Company intelligence / Profile preview

NightHawk Biosciences, Inc.

Morrisville, North Carolina, USAeuropeanpharmaceuticalreview.com ↗

Ownership: Private
Employees: ~75
Development stage: Phase 2

Overview

The company’s lead program HS‑110 completed enrollment in a Phase 2 trial for NSCLC in combination with checkpoint inhibitors. PTX‑35 entered a first-in-human Phase 1 trial for advanced solid tumors. Early results focus on safety and immune activation endpoints[3][6].

Therapeutic areas: OncologyInfectious Diseases
Modalities: Immunotherapies (cell-based therapies)monoclonal antibodies
Industry: Biotech

Drug pipeline

12 assets

viagenpumatucel-L

11 more assets in the full pipeline.

Request access →

Partnerships

Collaborations with University of Miami Miller School of Medicinegrant from Cancer Prevention and Research Institute of Texas for PTX–35 development[6][7]

Beyond the preview

Go deeper on NightHawk Biosciences, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NightHawk Biosciences, Inc..

Explore the full profile